Developing novel genome editing tools
In this Q&A, Dr Stephen Jones from Vilnius University Life Sciences Center discusses his work on the recent developments in genome editing tools at the university.
List view / Grid view
In this Q&A, Dr Stephen Jones from Vilnius University Life Sciences Center discusses his work on the recent developments in genome editing tools at the university.
Researchers discovered that glioblastoma cells rely on biotin distribution for growth, leading to possible future drug combinations.
Having identified the histone demethylase KDM5A as a multiple myeloma target, researchers developed a KDM5 inhibitor to treat the cancer.
A team has developed a new way to discover peptide therapeutics that inhibit HDAC enzymes and are effective against cancer.
New findings suggest that late-onset Alzheimer's Disease (AD) is driven by epigenetic changes in the brain.
A drug-like compound that can inhibit a key family of enzymes associated with several types of cancer has been developed and tested successfully in cells.
A new microfluidic technology has been developed which can profile histone modifications with as few as 100 cells per assay.
Researchers have shown how ATAD2, a histone chaperone protein, may load histones on to DNA in order to create the chromatin structure.
Researchers have shown that histones are vital in silencing genes and that their position is inherited in new cells, providing insight into how cancer cells can become resistant to therapy.
Frizzled receptors, from the GPCR family, could soon be a target to treat numerous diseases such as cancer, fibrosis and CVD...
9 July 2015 | By Victoria White
Researchers at the University of Liverpool's Institute of Infection and Global Health have discovered a common cause of heart damage in patients with sepsis...